Last updated: September 8, 2026
Tanzeum, the brand name for albiglutide, was a once-weekly GLP-1 receptor agonist developed and marketed by GlaxoSmithKline. The FDA approved it in 2014 for adults with Type 2 diabetes, but the product failed to gain durable share against Victoza, Trulicity, Bydureon and later Ozempic. GSK withdrew Tanzeum from the U.S. market in 2017 for commercial reasons, not because of a new safety finding. The withdrawal eliminated current product revenue, ended the commercial rationale for further lifecycle management and left albiglutide without a meaningful generic or biosimilar market.
What is Tanzeum and how did it compete in the GLP-1 market?
Tanzeum is a recombinant GLP-1 receptor agonist containing a modified GLP-1 sequence fused to human albumin. The albumin fusion extended its half-life and allowed once-weekly subcutaneous dosing. The product was administered using a prefilled pen at starting and maintenance doses of 30 mg or 50 mg.[1]
| Attribute |
Tanzeum |
| Active ingredient |
Albiglutide |
| Sponsor |
GlaxoSmithKline |
| FDA application |
BLA 125431 |
| FDA approval |
April 15, 2014 |
| Therapeutic area |
Type 2 diabetes |
| Administration |
Once-weekly subcutaneous injection |
| Initial U.S. dose |
30 mg weekly |
| Maintenance dose |
30 mg or 50 mg weekly |
| Product class |
GLP-1 receptor agonist |
| U.S. withdrawal |
Announced in 2017 |
| Primary commercial issue |
Weak market uptake and portfolio economics |
| Current U.S. commercial status |
No marketed product |
Tanzeum entered a rapidly expanding but increasingly competitive class. Its central commercial advantages were weekly dosing and GLP-1 efficacy. Its disadvantages included limited brand momentum, a complex pen presentation, lack of a strong first-mover position and an unfavorable competitive environment dominated by Novo Nordisk and Eli Lilly.
The product also entered a market where physicians were already familiar with Victoza and where Trulicity offered a competing once-weekly option. Later, Ozempic delivered stronger efficacy and became a major commercial benchmark for the class.
When did Tanzeum lose exclusivity and when was it withdrawn?
Tanzeum’s practical commercial exclusivity ended with GSK’s decision to withdraw it. GSK announced in July 2017 that it would discontinue Tanzeum in the United States because of limited use and commercial considerations.[2]
The withdrawal was not announced as a response to a product recall, a newly identified safety signal or an FDA enforcement action. Existing patients were advised to transition to alternative treatments because continued supply could not be guaranteed.
Tanzeum exclusivity timeline
| Date |
Event |
| 2012 |
GSK acquired Human Genome Sciences, bringing albiglutide into the GSK portfolio |
| April 2014 |
FDA approved Tanzeum for Type 2 diabetes |
| 2014 |
U.S. commercial launch |
| 2015-2016 |
Product remained a minor competitor in the GLP-1 class |
| July 2017 |
GSK announced U.S. discontinuation for commercial reasons |
| 2018 |
HARMONY Outcomes cardiovascular data were published after commercial withdrawal |
| Post-2017 |
No durable U.S. commercial presence and no marketed follow-on product |
The timing was commercially unfavorable. GSK withdrew Tanzeum before the publication of HARMONY Outcomes, the large cardiovascular outcomes trial that later showed a statistically significant reduction in major adverse cardiovascular events compared with placebo.[3] The clinical result improved the product’s scientific profile but arrived too late to reverse the commercial decision.
What were Tanzeum’s sales and financial trajectory?
Tanzeum never became a material growth product for GSK. Public GSK reporting treated the asset as a small diabetes product within a much larger pharmaceutical portfolio. The company did not develop Tanzeum into a major revenue platform comparable with later GLP-1 leaders.
The financial trajectory had four phases:
- Development and regulatory investment before approval.
- A limited launch with low market penetration.
- Commercial retrenchment as competitive pressure increased.
- Product withdrawal and termination of future revenue.
Revenue trajectory
GSK did not establish Tanzeum as a separately disclosed blockbuster product in its principal annual reporting. Reported sales were modest relative to the company’s major respiratory, HIV and oncology products. After discontinuation, Tanzeum ceased to generate meaningful ongoing product revenue.
The key financial consequence was not a large revenue decline from Tanzeum itself. It was the loss of potential future value from a GLP-1 asset in a market that later expanded rapidly. GSK exited before the class became one of the most valuable areas in diabetes and obesity medicine.
| Financial factor |
Effect on Tanzeum |
| Small launch base |
Limited initial revenue |
| Strong competition |
Restricted prescription growth |
| Weak brand adoption |
Reduced commercial scale |
| Manufacturing and distribution complexity |
Lowered portfolio attractiveness |
| Withdrawal before cardiovascular data |
Prevented late-stage repositioning |
| No obesity indication |
Limited addressable market |
| No post-withdrawal supply |
Eliminated future product sales |
The opportunity cost was substantial in retrospect. The GLP-1 market later benefited from expanded cardiovascular, renal, obesity and weight-management demand. Tanzeum had a validated mechanism and weekly administration, but GSK did not retain the commercial position needed to capture that growth.
How did Tanzeum compare with competing GLP-1 drugs?
Tanzeum competed with injectable GLP-1 receptor agonists, but its commercial performance lagged the leading products.
| Product |
Company |
Dosing |
Commercial position |
| Tanzeum |
GSK |
Once weekly |
Withdrawn after weak uptake |
| Victoza |
Novo Nordisk |
Once daily |
Established early leader |
| Trulicity |
Eli Lilly |
Once weekly |
Strong weekly injectable competitor |
| Bydureon |
AstraZeneca |
Once weekly |
Established but later lost share |
| Ozempic |
Novo Nordisk |
Once weekly |
Later class leader |
| Rybelsus |
Novo Nordisk |
Once daily oral |
Expanded GLP-1 use through oral dosing |
Tanzeum’s weekly dosing did not create sufficient differentiation. Trulicity provided a comparable weekly schedule with a simpler market proposition. Ozempic later raised the efficacy and demand standard for the class.
Tanzeum also lacked an obesity label. That omission became commercially important as GLP-1 demand expanded beyond glycemic control. Although the product’s biology may have supported weight loss, GSK did not establish a branded obesity franchise around albiglutide.
What cardiovascular evidence did Tanzeum generate?
The HARMONY Outcomes trial evaluated albiglutide in more than 9,400 patients with Type 2 diabetes and established cardiovascular disease. The trial reported a reduction in major adverse cardiovascular events compared with placebo, with a hazard ratio of approximately 0.78.[3]
The result placed albiglutide among GLP-1 therapies with demonstrated cardiovascular benefit. It also showed that Tanzeum’s clinical value was stronger than its market performance suggested.
The commercial impact was limited for three reasons:
- The trial readout came after GSK had decided to withdraw the product.
- The product was no longer supported by an active commercial infrastructure.
- Physicians had already moved toward competing GLP-1 therapies with stronger brand penetration.
The delayed cardiovascular evidence illustrates the mismatch between Tanzeum’s clinical development timeline and its commercial lifecycle.
What patents protected Tanzeum?
Tanzeum was protected by a combination of biologic composition, albumin-fusion, manufacturing and therapeutic-use intellectual property. The relevant patent categories included:
- Albiglutide and related GLP-1 fusion proteins.
- Albumin-linked peptide constructs.
- Recombinant production methods.
- Protein purification and formulation processes.
- Methods of treating Type 2 diabetes with once-weekly albiglutide.
The FDA approval occurred under a biologics license application rather than a conventional small-molecule NDA. Patent analysis therefore required review of GSK and predecessor Human Genome Sciences patent families, FDA biologics records and any applicable regulatory exclusivity.
Patent strength and practical enforceability
Tanzeum’s patent estate had technical breadth because the product required a specific protein construct and a recombinant manufacturing process. The estate was not commercially strong enough to support a long-term franchise after GSK abandoned active marketing.
The key distinction is between theoretical patent coverage and economic patent value. A patent covering albiglutide or its manufacturing process could remain legally relevant after commercial withdrawal, but its value would be limited if:
- No sponsor continued product supply.
- The originator did not pursue litigation.
- No follow-on manufacturer had entered the market.
- The drug had limited clinical demand compared with competing GLP-1 products.
Public sources do not support treating Tanzeum as an active patent-exclusivity asset comparable with currently marketed GLP-1 products. Its commercial protection ended in practice when GSK exited.
What was Tanzeum’s Orange Book and FDA status?
Tanzeum was approved as a biologic under BLA 125431. The FDA label identifies albiglutide as a prescription injectable for Type 2 diabetes.[1]
Because Tanzeum was approved as a biologic, the principal follow-on pathway would be a biosimilar application under section 351(k) of the Public Health Service Act rather than an ANDA under the Hatch-Waxman framework. In practice, no biosimilar or interchangeable product has created a competitive market around albiglutide.
FDA regulatory status
| Regulatory issue |
Status |
| Original approval |
FDA approved |
| BLA |
125431 |
| Product availability |
Discontinued |
| Safety-based withdrawal |
No |
| Commercial withdrawal |
Yes |
| Current U.S. market |
No marketed Tanzeum product |
| Generic pathway |
Not a conventional ANDA opportunity |
| Biosimilar competition |
No established commercial competitor |
| Current lifecycle strategy |
None publicly active |
The Orange Book is primarily designed for approved drugs listed under the NDA framework. For Tanzeum, biologic approval records and FDA discontinuation information are more relevant than a conventional generic-drug patent analysis.
Did any companies challenge Tanzeum’s patents under Paragraph IV?
No significant public Paragraph IV challenge became a defining feature of Tanzeum’s market history.
Paragraph IV litigation is associated with abbreviated new drug applications for small-molecule products. Tanzeum was approved as a biologic, so a follow-on competitor would generally pursue the biosimilar framework rather than submit a conventional ANDA with a Paragraph IV certification.
No major public biosimilar litigation, settlement or launch agreement materially affected albiglutide. The absence of litigation reflected the product’s commercial withdrawal and limited residual market value, not necessarily the absence of technically defensible intellectual property.
What manufacturing and formulation barriers affected Tanzeum?
Albiglutide’s manufacturing requirements were more complex than those of a conventional oral diabetes product. The drug was a recombinant fusion protein requiring cell-based production, purification, analytical characterization and sterile injectable manufacturing.
The principal barriers included:
- Control of protein expression and folding.
- Consistent fusion-protein integrity.
- Removal of process-related impurities.
- Maintenance of potency and stability.
- Sterile filling and device compatibility.
- Reproducibility of the prefilled injection system.
These barriers could deter rapid follow-on development. They did not, however, solve Tanzeum’s central commercial problem: inadequate demand relative to the cost of maintaining a branded biologic infrastructure.
Which companies challenged GSK in the GLP-1 market?
The main competitive pressure came from companies with stronger diabetes franchises and greater commercial scale.
Novo Nordisk
Novo Nordisk had a deep diabetes portfolio, established prescriber relationships and extensive GLP-1 development experience. Victoza was already established when Tanzeum launched, and Ozempic later became a major market leader.
Eli Lilly
Eli Lilly’s Trulicity provided a direct once-weekly competitor. Its dosing convenience, commercial execution and subsequent clinical positioning made it particularly important to Tanzeum’s failure to gain share.
AstraZeneca
AstraZeneca marketed Bydureon and had an established presence in injectable diabetes therapy. Although Bydureon had its own limitations, it contributed to a crowded weekly GLP-1 segment.
The competitive landscape rewarded products with superior efficacy, simple delivery, strong cardiovascular data and a credible long-term franchise. Tanzeum achieved only part of that profile.
What licensing deals and corporate transactions affected Tanzeum?
The most important transaction was GSK’s 2012 acquisition of Human Genome Sciences for approximately $3 billion. Human Genome Sciences had partnered with GSK on development programs, including albiglutide. The acquisition gave GSK full corporate control over the asset and related development rights.[4]
The transaction increased GSK’s exposure to albiglutide but also concentrated the commercial risk. After the acquisition, GSK carried the cost of development, manufacturing, regulatory maintenance and commercialization. The subsequent withdrawal meant the asset did not produce a return commensurate with the transaction’s broader strategic rationale.
No later licensing deal restored albiglutide’s commercial position after GSK’s withdrawal.
What generic launch and biosimilar risks exist for Tanzeum?
Current generic launch risk is low because Tanzeum is not actively marketed and no established follow-on competitor has entered the U.S. market.
A theoretical biosimilar could face several barriers:
- Limited commercial demand for an inactive brand.
- Need for a reference product and analytical comparability package.
- Complex manufacturing requirements.
- Possible residual patent or regulatory barriers.
- Competition from newer GLP-1 therapies.
- Lack of an established reimbursement base.
The more important risk is not erosion of Tanzeum revenue. That revenue has already disappeared. The relevant issue is whether albiglutide could be revived or repurposed by another company. Current market economics make that scenario unlikely without a new clinical positioning, a materially improved delivery system or a new indication.
How does Tanzeum compare with current GLP-1 market leaders?
Tanzeum’s product characteristics were adequate for the class but insufficient for the market.
| Commercial criterion |
Tanzeum |
Current leading GLP-1 products |
| Weekly dosing |
Yes |
Yes for major injectable leaders |
| Cardiovascular outcomes |
Positive |
Positive for several leading products |
| Obesity positioning |
No |
Strong for selected products |
| Oral option |
No |
Available through semaglutide |
| Brand scale |
Limited |
Very strong for Novo Nordisk and Eli Lilly |
| Current availability |
No |
Broad |
| Franchise depth |
Limited |
Diabetes, obesity and cardiovascular indications |
| Revenue potential |
Exhausted |
High and expanding |
Tanzeum was clinically credible but commercially under-positioned. It entered a competitive class without a clear enough point of difference and exited before the market’s later expansion.
What is the investment and licensing conclusion for Tanzeum?
Tanzeum is a discontinued biologic asset with no meaningful standalone revenue trajectory. Its historical value came from clinical validation of albiglutide and its cardiovascular profile. Its present value is constrained by discontinued supply, absent commercial infrastructure, intense competition and the lack of an active lifecycle strategy.
For investors, Tanzeum is best analyzed as a case of foregone GLP-1 opportunity rather than as a current revenue-generating asset. For licensing teams, the asset would require a full redevelopment plan, not a conventional relaunch. For patent analysts, the relevant question is whether any surviving claims could block a new entrant, not whether the estate can protect an active branded franchise.
Key Takeaways
- Tanzeum was FDA approved in 2014 as once-weekly albiglutide for Type 2 diabetes.
- GSK withdrew the product in 2017 for commercial reasons.
- No material current Tanzeum revenue remains.
- The product faced direct competition from Victoza, Trulicity and Bydureon, followed by stronger competition from Ozempic.
- HARMONY Outcomes later demonstrated cardiovascular benefit, but the data arrived after the commercial withdrawal.
- Tanzeum was a biologic, so biosimilar analysis is more relevant than conventional Paragraph IV generic litigation.
- No major public Paragraph IV challenge, biosimilar launch or settlement shaped the product’s market history.
- GSK’s acquisition of Human Genome Sciences was the key transaction affecting ownership and development control.
- The patent estate may have had technical breadth, but its practical commercial value declined sharply after withdrawal.
- Tanzeum is not a current competitive threat or a material source of GSK revenue.
FAQs
Why did GSK discontinue Tanzeum?
GSK discontinued Tanzeum because of limited market use and commercial considerations. The decision was not announced as a safety withdrawal.
Did Tanzeum have better cardiovascular data than competing GLP-1 drugs?
HARMONY Outcomes showed a significant reduction in major adverse cardiovascular events. The result was clinically important but was reported after GSK had already decided to exit the product.
Can a company launch a generic version of Tanzeum?
A conventional generic is not the principal regulatory route because Tanzeum was approved as a biologic. A follow-on developer would generally need to pursue the biosimilar pathway.
Is albiglutide still available outside the United States?
GSK also marketed albiglutide under the Eperzan name in certain non-U.S. markets. The product’s broader commercial availability declined after GSK ended its development and commercialization strategy.
Did Tanzeum generate blockbuster revenue for GSK?
No. Tanzeum remained a small product within GSK’s portfolio and did not become a blockbuster. Its commercial trajectory ended before the GLP-1 class reached its later scale.
References
- U.S. Food and Drug Administration. (2014). Tanzeum (albiglutide) prescribing information.
- GlaxoSmithKline plc. (2017). GSK to discontinue Tanzeum in the United States.
- Hernandez, A. F., Green, J. B., Janmohamed, S., et al. (2018). Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease. The Lancet, 392(10157), 1519-1529.
- GlaxoSmithKline plc. (2012). GSK completes acquisition of Human Genome Sciences.
